Pretreatment to Enhance Protoporphyrin IX Accumulation in Photodynamic Therapy

被引:91
作者
Gerritsen, M. J. P. [1 ]
Smits, T. [1 ]
Kleinpenning, M. M. [1 ]
van de Kerkhof, P. C. M. [1 ]
van Erp, P. E. J. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, NL-6500 HB Nijmegen, Netherlands
关键词
Photodynamic therapy; Adjuvant treatment; Literature review; IRON-CHELATING AGENT; BASAL-CELL CARCINOMA; 5-AMINOLEVULINIC ACID; IN-VITRO; AMINOLEVULINIC-ACID; PORPHYRIN PRODUCTION; TOPICAL APPLICATION; SKIN-CANCER; DELIVERY; FLUORESCENCE;
D O I
10.1159/000183753
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100227 [皮肤病学];
摘要
The response rates of photodynamic therapy ( PDT) vary widely. Limited uptake of topically applied 5-aminolaevulinic acid ( ALA), or its methyl ester ( MAL), and suboptimal production of protoporphyrin IX ( PpIX) may account for these differences. Recently, we demonstrated that hyperkeratosis is an important negative factor in ALA uptake. This review has its focus on pretreatment of the skin in order to improve the clinical outcome of ALA/MAL PDT. Pretreatment of hyperkeratosis can be achieved with keratolytics, curettage/debulking, tape stripping, microdermabrasion or laser ablation. Penetration enhancers may alter the composition or organization of the intercellular lipids of the stratum corneum. Several studies have been performed on the use of dimethyl sulfoxide, azone, glycolic acid, oleic acid and iontophoresis to increase the penetration of ALA. As PpIX production is also dominated by temperature-dependent processes, elevating skin temperature during ALA application may also improve treatment results. Another approach is the use of additives that interact with the heme biosynthetic pathway, e. g. by removing ferrous iron with iron-chelating substances such as: ethylenediaminetetraacetic acid; 3-hydroxypyridin-4-ones; 1,2-diethyl-3-hydroxypyridin-4-one-hydrochloride; and desferrioxamine. In conclusion, simple pretreatments or additions to the regular practice of PDT, aimed to optimize intralesional PpIX content, improve the clinical outcome. Copyright (C) 2008 S. Karger AG, Basel
引用
收藏
页码:193 / 202
页数:10
相关论文
共 41 条
[1]
The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells [J].
Berg, K ;
Anholt, H ;
Bech, O ;
Moan, J .
BRITISH JOURNAL OF CANCER, 1996, 74 (05) :688-697
[2]
A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma [J].
Berroeta, L. ;
Clark, C. ;
Dawe, R. S. ;
Ibbotson, S. H. ;
Fleming, C. J. .
BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (02) :401-403
[3]
Boddé HE, 2002, PHOTOCHEM PHOTOBIOL, V75, P418, DOI 10.1562/0031-8655(2002)075<0418:QOTDAA>2.0.CO
[4]
2
[5]
Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma [J].
Campbell, S. M. ;
Morton, C. A. ;
Alyahya, R. ;
Horton, S. ;
Pye, A. ;
Curnow, A. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (02) :387-393
[6]
The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy [J].
Choudry, K ;
Brooke, RCC ;
Farrar, W ;
Rhodes, LE .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (01) :124-130
[7]
Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid [J].
Curnow, A ;
MacRobert, AJ ;
Bown, SG .
LASERS IN SURGERY AND MEDICINE, 2006, 38 (04) :325-331
[8]
Curnow A, 2007, J ENVIRON PATHOL TOX, V26, P89
[9]
A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy [J].
De Rosa, FS ;
Marchetti, JM ;
Thomazini, JA ;
Tedesco, AC ;
Lopes, MV ;
Bentley, B .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (03) :359-366
[10]
Donnelly RF, 2008, J CONTROL RELEASE, V129, P154, DOI 10.1016/j.jconrel.2008.05.002